Humulin Nph (Insulin Human (Rdna))

Humulin Nph is indicated for the management of hyperglycemia in adults with diabetes when basal insulin coverage is required.

• Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus when oral agents or other injectables do not achieve target glucose levels.
• Adjunct therapy during pregnancy or lactation under specialist supervision, when basal insulin is needed.
• Use in combination with rapid‑acting insulin analogues to provide basal insulin support.
• Adjustment of basal insulin dose in response to changes in diet, physical activity, or illness.

• Humulin Nph contains recombinant human insulin that binds to the insulin receptor on cell membranes. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the plasma membrane. This enhances glucose uptake in muscle and adipose tissue and suppresses hepatic gluconeogenesis, resulting in lowered plasma glucose concentrations over an intermediate duration. The protamine component slows absorption, extending the insulin’s action profile.

Adverse reactions to Humulin Nph may vary in frequency and severity; they are typically categorized as common or serious.

Common

• Hypoglycemia, especially if meals are missed or dosing is excessive.
• Injection site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycemic control.
• Lipodystrophy at the injection site, presenting as lipoatrophy or lipohypertrophy.
• Transient blurred vision during periods of rapid glucose change.
• Mild gastrointestinal discomfort such as nausea or abdominal fullness.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Insulin antibody formation causing unpredictable glucose control.
• Edema or fluid retention, particularly in patients with cardiac or renal impairment.

When prescribing Humulin Nph, clinicians should evaluate patient-specific factors and monitor for conditions that may affect insulin therapy.

• Renal or hepatic impairment may alter insulin clearance; dose adjustments may be required.
• Elderly patients are at higher risk for hypoglycemia and should be started on lower doses.
• Pregnancy and lactation status should be confirmed; insulin is the preferred agent but dosing must be individualized.
• Concurrent illness, infection, or stress can increase insulin requirements and precipitate hyperglycemia.
• Patients with a history of severe allergic reactions to insulin or protamine should avoid this product.
• Regular monitoring of blood glucose and HbA1c is essential to assess therapeutic effectiveness.

Humulin Nph may interact with other medicines that influence glucose metabolism, insulin action, or protein binding.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without proper dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, increasing the risk of unnoticed low blood glucose.
• High‑dose corticosteroids that markedly raise blood glucose, potentially overwhelming basal insulin coverage.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which can potentiate hypoglycemia.
• Thiazide diuretics that may increase blood glucose levels, requiring closer monitoring.
• Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations.